CAS: 53296-10-9; (2R,3R,4S,5R)-2-(6-Amino-2-(Phenylamino)-9H-Purin-9-yl)-5-(Hydroxymethyl)Tetrahydrofuran-3,4-Diol

该化合物是一种纯核核素衍生物,其特点是在肋骨糖的2个位置上存在一种代谢性骨干,以苯基氨基质组替代;这种复合物具有核素的典型特性,包括由于存在氨基和氢氧的功能组,能够参与氢结合的能力;在极地溶剂中可溶解,反映其具有水利性,对核素很常见;苯基胺替代可影响其生物活动,可能影响与细胞过程中的受体或酶的相互作用;这种化合物可能对药理学研究感兴趣,特别是与在各种生理功能中发挥关键作用的抗疟素受体有关的研究感兴趣;此外,其结构特征可能允许进一步修改,以提高其治疗潜力或选择性;同许多核素类类类似一样,了解其稳定性,再活性和生物相互作用对于探索其在药化学中的应用至关重要.

结构式图片

物理性质

MSDS等安全信息

上下游产品

CAS号622-34-4 phenylcyanamide | CAS号23192-64-5 1H-Imidazole-4-... | CAS号79715-27-8 ethyl 5-amino-1... | CAS号622-16-2 2-氯-5-异氰酸硝基苯 | CAS号53296-13-2 N-Phenyl-guanos... | CAS号2627-69-2 阿卡地辛 | CAS号103-72-0 异硫氰酸苯酯

合成工艺路线路线简述

  • 合成目标产物 2-Phenylaminoadenosine 主要起始原料 Aicar
  • (文献来源)合成步骤主要原料 Aicar
📜阿卡地新置于氨体系中,用 吡啶,甲醇,二氯甲烷 作为反应溶剂,化学反应 21.0H,反应生成 2-苯基氨基腺苷
参考文献:Synthesis Of 2-Phenylaminoadenosine From Imidazole Nucleosides.
标题:Synthesis Of 2-Phenylaminoadenosine From Imidazole Nucleosides.
摘要:开发了三种合成2-苯胺腺苷(1,Cv-1808)的方法,这是一种具有持久作用的强效冠状动脉扩张剂.1)5-氨基-4-氰基-1-(β-D-呋喃核糖基)咪唑(7)与苯基异硫氰酸酯反应,反应生成7-亚氨基-5-苯胺基-3-(β-D-呋喃核糖基)咪唑并[4,5-D][1,3]噻嗪(11),后者经碱性处理后重排为6-巯基-2-苯胺基-9-(β-D-呋喃核糖基)嘌呤(12).甲基化后,12反应生成6-甲硫基衍生物(14),通过氨处理转化为1.2)5-氨基-4-氰基-1-(β-D-呋喃核糖基)咪唑(7)在甲醇氨中与苯基氰胺反应,反应生成1和2-氨基腺苷作为副产品.3)通过5-氨基-1-(2,3,5-三-O-丙酰基-β-D-呋喃核糖基)咪唑-4-羧酰胺(4)与meerwein试剂处理后去酰化,直接得到乙基5-氨基-1-(β-D-呋喃核糖基)-4-羧基咪唑盐(21B),然后通过与苯基氰胺反应反应生成1.
DOI:10.1248/cpb.29.1870

海关参考信息

专利信息


专利号:US-6645513-B2
优先权日:1998-10-26
标题 :Treatment of skin with adenosine or adenosine analog
发明人：DOBSON JR JAMES G; ETHIER MICHAEL F
权利人:UNIV MASSACHUSETTS
摘要:Methods for enhancing the condition of non-diseased skin by application of compositions containing adenosine or an adenosine analog are disclosed. Also disclosed are methods for increasing DNA synthesis or protein synthesis in dermal cells, and methods for increasing dermal cell size, by application of compositions containing adenosine.

专利号:US-12036300-B2
优先权日:2021-03-31
标题:Methods and compositions for improving skin
发明人：LIAO I-CHIEN; BRIEVA PATRICIA; JUCHAUX FRANCK; BOUEZ CHARBEL; ZHENG QIAN; QIAN KUN
权利人:OREAL
摘要:A method for managing skin tone comprising reducing the synthesis of melanin by applying a skin treatment composition to skin. The skin treatment composition may include about 0.1 to about 25 wt. % of acetyl trifluoromethylphenyl valylglycine; about 0.5 to about 30 wt. % of a polyol; about 0.1 to about 30 wt. % of a silicone, fatty compound, or a mixtures thereof, wherein the skin treatment composition is an emulsion, and all weight percentages are based on the total weight of the skin treatment composition.

专利号:IL-161608-A
优先权日:2001-10-25
标 题 :Synthesis and therapeutic use of 2-aralkoxyadenosines and 2-alkoxyadenosines

其他信息查阅

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

实用工具

⚠️全国化工行业净网倡议书
📋制造商识别码
📖 海关编码查询
📝MSDS生成器

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Cornfield LJ, Hu S, Hurt SD, Sills MA. [3H]2-phenylaminoadenosine ([3H]CV 1808) labels a novel adenosine receptor in rat brain. J Pharmacol Exp Ther. 1992 Nov;263(2):552-61.
3: Tanabe M, Terashita Z, Nishikawa K, Hirata M. Inhibition of coronary circulatory failure and thromboxane A2 release during coronary occlusion and reperfusion by 2-phenylaminoadenosine (CV-1808) in anesthetized dogs. J Cardiovasc Pharmacol. 1984 May-Jun;6(3):442-8.

合成参考文献


参考文献:10.1021/jm00093a022
摘要:Homma H, Watanabe Y, Abiru T, Murayama T, Nomura Y, Matsuda A. Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity. J Med Chem. 1992 Jul 24;35(15):2881–90. doi: 10.1021/jm00093a022.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知